2025 Q3 -tulosraportti
Vain PDF
28 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 27.8. | |
| 2025 Q1 -tulosraportti | 22.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·20.12.I've been thinking a bit about Merck's acquisition of Sotatercept. Or that they acquired all of Acceleron Pharma. In 2021. Sotatercept was in phase 3 then. A huge sum, but Merck went all in with a bid. Only now after 10 years in Cereno do I think about this. Yes, it can be a good acquisition sum, but we still have 2-3 years before we approach phase 3 studies. I find it strange again that anyone at all thinks a deal can come at any time 🤔 I'm holding mine. But also interesting to see how the Acceleron share developed towards the acquisition 🤔 there was no 10x increase..
·2 päivää sittenHi Sjabby…. Nice to see that you are more positive about Cereno's future. I actually think you always were, but wanted in cheaper 😉 Anyway regarding the deal… By deal is not meant only a pure exit but also partnership. Now the cash is replenished, but that doesn't stop any potential partner from coming in. Then there are countless possible scenarios for what the partnership could look like. Regardless, we are heading towards a fantastic year 2026 where knowledge and patience will pay off. Good luck, guys and girls 😉
11.12.11.12.The P2B study for CS1 will have topline readouts ready sometime in Q4 of 2028. If we take the assumption (to clarify, I have not checked statistics on this) that most BP buyouts of a drug are done post p2 and pre p3 that would mean we’re still years from an exit. Patient mans game, I suppose. But there’s also plenty of good in the situation. Cereno resolved their finances with much better conditions than what I could have ever predicted, so Kudos to them. As long as cashburn doesn’t significantly increase the finances are well supported for a good while. I also eagerly await the new data for CS014 they’re about to release. Hopefully it will support the stock price to stabilize.
·12.12.Are there examples of bidding wars between BP recently, the bids often come from zero holdings or smaller stakes? 🤔
8.12.8.12.Over 30 days has passed since FDA application for phase2b was submitted. I assume it has been approved!
·3.12.Latest analysis from Edison here: https://www.edisongroup.com/research/armed-and-ready-for-phase-ii/BM-2503/
·9.12.I don't quite know what your inv- philosophy is. It seems we are not very disagreed, if I look back at what you have written before. My small main point was that the future has not arrived yet, even if one buys an analysis that quantifies it. I currently have no akskjer in CRNO. Waiting for the 5-level (which may never kommmer). Then I will perhaps make a new assessment based on the future that the company may seem to have -then, not now. But thanks for a thought-provoking meldiingsutveksling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
28 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20.12.I've been thinking a bit about Merck's acquisition of Sotatercept. Or that they acquired all of Acceleron Pharma. In 2021. Sotatercept was in phase 3 then. A huge sum, but Merck went all in with a bid. Only now after 10 years in Cereno do I think about this. Yes, it can be a good acquisition sum, but we still have 2-3 years before we approach phase 3 studies. I find it strange again that anyone at all thinks a deal can come at any time 🤔 I'm holding mine. But also interesting to see how the Acceleron share developed towards the acquisition 🤔 there was no 10x increase..·2 päivää sittenHi Sjabby…. Nice to see that you are more positive about Cereno's future. I actually think you always were, but wanted in cheaper 😉 Anyway regarding the deal… By deal is not meant only a pure exit but also partnership. Now the cash is replenished, but that doesn't stop any potential partner from coming in. Then there are countless possible scenarios for what the partnership could look like. Regardless, we are heading towards a fantastic year 2026 where knowledge and patience will pay off. Good luck, guys and girls 😉
- 11.12.11.12.The P2B study for CS1 will have topline readouts ready sometime in Q4 of 2028. If we take the assumption (to clarify, I have not checked statistics on this) that most BP buyouts of a drug are done post p2 and pre p3 that would mean we’re still years from an exit. Patient mans game, I suppose. But there’s also plenty of good in the situation. Cereno resolved their finances with much better conditions than what I could have ever predicted, so Kudos to them. As long as cashburn doesn’t significantly increase the finances are well supported for a good while. I also eagerly await the new data for CS014 they’re about to release. Hopefully it will support the stock price to stabilize.·12.12.Are there examples of bidding wars between BP recently, the bids often come from zero holdings or smaller stakes? 🤔
- 8.12.8.12.Over 30 days has passed since FDA application for phase2b was submitted. I assume it has been approved!
- ·3.12.Latest analysis from Edison here: https://www.edisongroup.com/research/armed-and-ready-for-phase-ii/BM-2503/·9.12.I don't quite know what your inv- philosophy is. It seems we are not very disagreed, if I look back at what you have written before. My small main point was that the future has not arrived yet, even if one buys an analysis that quantifies it. I currently have no akskjer in CRNO. Waiting for the 5-level (which may never kommmer). Then I will perhaps make a new assessment based on the future that the company may seem to have -then, not now. But thanks for a thought-provoking meldiingsutveksling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 27.8. | |
| 2025 Q1 -tulosraportti | 22.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
Vain PDF
28 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 27.8. | |
| 2025 Q1 -tulosraportti | 22.5. | |
| 2024 Q4 -tulosraportti | 25.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·20.12.I've been thinking a bit about Merck's acquisition of Sotatercept. Or that they acquired all of Acceleron Pharma. In 2021. Sotatercept was in phase 3 then. A huge sum, but Merck went all in with a bid. Only now after 10 years in Cereno do I think about this. Yes, it can be a good acquisition sum, but we still have 2-3 years before we approach phase 3 studies. I find it strange again that anyone at all thinks a deal can come at any time 🤔 I'm holding mine. But also interesting to see how the Acceleron share developed towards the acquisition 🤔 there was no 10x increase..·2 päivää sittenHi Sjabby…. Nice to see that you are more positive about Cereno's future. I actually think you always were, but wanted in cheaper 😉 Anyway regarding the deal… By deal is not meant only a pure exit but also partnership. Now the cash is replenished, but that doesn't stop any potential partner from coming in. Then there are countless possible scenarios for what the partnership could look like. Regardless, we are heading towards a fantastic year 2026 where knowledge and patience will pay off. Good luck, guys and girls 😉
- 11.12.11.12.The P2B study for CS1 will have topline readouts ready sometime in Q4 of 2028. If we take the assumption (to clarify, I have not checked statistics on this) that most BP buyouts of a drug are done post p2 and pre p3 that would mean we’re still years from an exit. Patient mans game, I suppose. But there’s also plenty of good in the situation. Cereno resolved their finances with much better conditions than what I could have ever predicted, so Kudos to them. As long as cashburn doesn’t significantly increase the finances are well supported for a good while. I also eagerly await the new data for CS014 they’re about to release. Hopefully it will support the stock price to stabilize.·12.12.Are there examples of bidding wars between BP recently, the bids often come from zero holdings or smaller stakes? 🤔
- 8.12.8.12.Over 30 days has passed since FDA application for phase2b was submitted. I assume it has been approved!
- ·3.12.Latest analysis from Edison here: https://www.edisongroup.com/research/armed-and-ready-for-phase-ii/BM-2503/·9.12.I don't quite know what your inv- philosophy is. It seems we are not very disagreed, if I look back at what you have written before. My small main point was that the future has not arrived yet, even if one buys an analysis that quantifies it. I currently have no akskjer in CRNO. Waiting for the 5-level (which may never kommmer). Then I will perhaps make a new assessment based on the future that the company may seem to have -then, not now. But thanks for a thought-provoking meldiingsutveksling.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt